Table 1.
Results for 2006-2012 Trend in Pharmaceutical Spending and Use of Antidementia and Antipsychotic Drugs.
| Coefficient | p value | |
|---|---|---|
| Alzheimer’s disease patients | ||
| Spending | ||
| Trend in total pharmaceutical spending | −6.41 | 0.134 |
| Spending on antidementia drugs | ||
| Trend | 6.09 | 0.002 |
| Trend change after January 2011 | −15.77 | 0.012 |
| Level change after January 2011 | 252.00 | 0.074 |
| Spending on antipsychotic drugs | ||
| All AD patients | ||
| Trend | −0.84 | 0.248 |
| Trend change after January 2012 | −25.52 | 0.027 |
| Level change after January 2012 | 648.67 | 0.033 |
| AD patients with no diagnosis of FDA-approved indications for antipsychotic drugs | ||
| Trend | −1.22 | 0.047 |
| Trend change after January 2012 | −22.13 | 0.020 |
| Level change after January 2012 | 567.57 | 0.024 |
| Utilization | ||
| Trend number of prescriptions for antidementia drugs | 0.01 | 0.045 |
| Trend number of prescriptions for antipsychotic drugs | ||
| All AD patients | 0.00 | 0.698 |
| AD patients with no diagnosis of FDA-approved indications for antipsychotic drugs | 0.00 | 0.337 |
| Patients with other forms of dementia | ||
| Spending | ||
| Trend in total pharmaceutical spending | −4.10 | 0.276 |
| Spending on antidementia drugs | ||
| Trend | 2.18 | 0.001 |
| Trend change after January 2011 | −6.44 | 0.002 |
| Level change after January 2011 | 109.44 | 0.016 |
| Spending on antipsychotic drugs | ||
| All patients with other forms of dementia | ||
| Trend | −0.11 | 0.861 |
| Trend change after January 2012 | −13.45 | 0.152 |
| Level change after January 2012 | 331.16 | 0.182 |
| Patients with other forms of dementia and no diagnosis of FDA-approved indications for antipsychotic drugs | ||
| Trend | −0.53 | 0.114 |
| Trend change after January 2012 | −8.63 | 0.090 |
| Level change after January 2012 | 217.25 | 0.106 |
| Utilization | ||
| Trend number of prescriptions for antidementia drugs | 0.01 | 0.005 |
| Trend number of prescriptions for antipsychotic drugs | ||
| All patients with other forms of dementia | 0.00 | 0.789 |
| Patients with other forms of dementia and no diagnosis of FDA-approved indications for antipsychotic drugs | 0.00 | 0.330 |
Note. Bold indicates significant results. Results obtained from ordinary least squares regression models. All models included quarter as a continuous time variable. The models constructed to evaluate the change in spending on antidementia drugs over time also included an indicator variable for the period after January 1, 2010, and an interaction term between the period after January 1, 2010, and quarter. The regression models constructed to test the change in spending on antipsychotic drugs included an indicator variable for the period after January 1, 2012, as well as an interaction term between post-January 1, 2012, and quarter. AD = Alzheimer’s disease; FDA = Food and Drug Administration.